Skip to content
Peptide research

Cardiogen

Category
Bioregulators
Administration routes
InjectableOral
Regulatory status
Not FDA-approved

A short synthetic bioregulator peptide marketed for heart health and cardiac anti-aging. Evidence is almost entirely animal and cell-culture: reduced heart-cell death and better survival after induced heart injury, with human data essentially absent. Animal work also shows it altering tumor-cell behavior, an unresolved concern for undiagnosed cancer, with no human safety record. Not an approved drug in the US; supply is unregulated research-grade material.

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.

Overview

Cardiogen is a synthetic four-amino-acid peptide (Ala-Glu-Asp-Arg) designed to specifically target heart tissue. Developed by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, it belongs to the class of short peptide bioregulators that penetrate into cell nuclei and interact directly with DNA to regulate gene expression. Unlike most peptides that work by binding to receptors on the cell surface, Cardiogen enters the cell and influences which genes are turned on or off in heart cells.

How it works in the body

A short bioregulator peptide (Ala-Glu-Asp-Arg) that targets cardiomyocytes (heart muscle cells). It enters these cells and interacts with regulatory DNA regions to normalize the expression of genes involved in heart muscle contraction, energy metabolism, and stress resistance.

Research overview

Cardiogen works by entering heart cells and binding to DNA and histone proteins (the structural proteins that package DNA), modulating which genes are expressed. In a laboratory study, it increased structural-protein expression in mouse embryonic fibroblasts. In rat myocardial cultures, it increased cardiomyocyte (heart muscle cell) proliferation and reduced p53 expression, suggesting less programmed cell death. A 2021 systematic review confirmed it binds to multiple histone proteins (H1, H2B, H3, H4) and modulates DNA processing depending on the cell's epigenetic state. However, the evidence base has significant limitations: no controlled human clinical trials have been published in peer-reviewed Western journals, and virtually all research comes from a single group — the Khavinson lab in Russia. The compound remains in the preclinical stage, and independent replication of its effects is needed before drawing firm conclusions about its potential.

Who researches Cardiogen?

Commonly researched by

  • People researching longevity and anti-aging interventions

    Studied for effects on aging pathways, cellular health, or lifespan extension.

  • People researching cardiovascular health

    Studied for effects on heart function, blood pressure, or vascular health.

  • People researching experimental oncology peptides

    Studied for effects on cancer cell targeting or tumor biology in preclinical research.

Important considerations for

  • Those who are pregnant or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Anyone under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Those with Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

Safety & interactions

General cautions

  • Pregnancy or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Children under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

How to read the ratings

Benefits
= confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Risks
= level of concern: High · Moderate · Low · Theoretical
Interactions
= direction with this peptide: Protective / Synergistic · Caution · Neutral

Risk summary(8)

Rated by level of concern

  • safety_data

    Moderate

    PubMed search for cardiogen peptide / AEDR (no safety or PK studies among the retrieved records); ClinicalTrials.gov query for cardiogen / Ala-Glu-Asp-Arg - no matching studies

  • Unknown long-term safety profile in humans

    Moderate

    No human studies located in PubMed or ClinicalTrials.gov

  • Possible immunogenic reactions (as with any exogenous peptide)

    Low

    General peptide immunology first principles; no immunogenicity study published for AEDR

  • Potential unknown interactions with cardiovascular medications

    Theoretical

    No interaction data located in PubMed

  • Gene expression modulation effects could theoretically have unintended consequences

    Theoretical

    Fedoreyeva LI et al., 'Interaction of short peptides with FITC-labeled wheat histones and their complexes with deoxyribooligonucleotides.' Biochemistry (Mosc) 2013;78(2):166-75 (PMID 23581987)

  • Tumor-modifying activity observed in animal models raises questions about effects in patients with undiagnosed cancers

    Moderate

    Bull Exp Biol Med 2009;148(3):433-6 (PMID 20396706); p53 downregulation per Adv Gerontol 2009 (PMID 20210190)

  • contraindications

    Moderate

    No FDA/EMA approval or labelling identified; no registered trials

  • note

    Low

    Review of all indexed cardiogen/AEDR citations in PubMed (PMIDs 36611900, 20210190, 20396706, 17152728)

Interaction summary(7)

Rated by direction with this peptide

  • Cytotoxic chemotherapy / patients with active or suspected malignancy

    CautionTheoretical

    Cardiogen measurably altered tumour growth and increased tumour-cell apoptosis in a rat M-1 sarcoma model, so its net effect alongside chemotherapy - or in someone with an undiagnosed cancer - is unpredictable and untested. No human data of any kind.

    Levdik NV, Knyazkin IV, Bull Exp Biol Med 2009;148(3):433-6 (PMID 20396706)

  • Anthracyclines (doxorubicin) and other cardiotoxic oncology agents

    CautionTheoretical

    A p53-lowering, anti-apoptotic action reported in rat myocardial explants might plausibly blunt anthracycline cardiotoxicity, but the same mechanism could equally shield tumour cells from p53-dependent killing. Neither direction has been tested, and the p53 finding itself is ex vivo rodent tissue.

    Mechanism-based inference from Adv Gerontol 2009 (PMID 20210190); no co-administration study exists in PubMed

  • ACE inhibitors / ARBs (e.g. lisinopril, losartan)

    NeutralTheoretical

    No combination study has been performed, so additive benefit cannot be claimed. Both are nominally directed at adverse post-infarct remodelling, but a shared therapeutic target is not evidence of synergy, and no pharmacokinetic interaction is predicted for a rapidly peptidase-cleared tetrapeptide.

    Mechanism-based inference from rat coronary-ligation data reported in Cells 2022 (PMID 36611900); no interaction or combination study

  • Beta-blockers (e.g. metoprolol, carvedilol)

    NeutralTheoretical

    AEDR has no described adrenergic, chronotropic, or hemodynamic activity and no shared metabolic pathway, so no meaningful interaction is expected - though this has never been formally checked.

    No published interaction or hemodynamic data for AEDR

  • Antiplatelet and anticoagulant therapy (aspirin, clopidogrel, DOACs)

    NeutralTheoretical

    No antiplatelet, fibrinolytic, or coagulation effect has been reported for AEDR; the only bleeding-adjacent observation in the literature is haemorrhagic necrosis within tumour tissue in the M-1 sarcoma model, which the authors read as a local tumour-vascular phenomenon rather than a systemic coagulation effect.

    Bull Exp Biol Med 2009;148(3):433-6 (PMID 20396706); no systemic coagulation data

  • Statins and other lipid-lowering agents

    NeutralTheoretical

    No overlap in target, transporter, or CYP metabolism is described, and short peptides are cleared by peptidases, so a pharmacokinetic interaction is not anticipated. Never formally studied.

    Mechanism-based inference; no published interaction data

  • Other Khavinson short-peptide bioregulators (e.g. Epitalon, Vesugen, Vilon)

    NeutralTheoretical

    These share a proposed peptide-DNA/histone mechanism, which makes overlapping or competing transcriptional effects conceivable when used together, but no combination has ever been studied.

    Khavinson VK, Popovich IG, Linkova NS, Mironova ES, Ilina AR. 'Peptide Regulation of Gene Expression: A Systematic Review.' Molecules 2021;26(22):7053 (PMID 34834147; PMC8619776)

Known risks(8)

  • safety_data

    Limited to preclinical animal studies; no formal human safety or toxicology data from controlled clinical trials

  • Unknown long-term safety profile in humans

  • Possible immunogenic reactions (as with any exogenous peptide)

  • Potential unknown interactions with cardiovascular medications

  • Gene expression modulation effects could theoretically have unintended consequences

  • Tumor-modifying activity observed in animal models raises questions about effects in patients with undiagnosed cancers

  • contraindications

    Not established due to lack of clinical data. Caution advised for individuals with active cancers, autoimmune conditions, or those taking immunosuppressive medications.

  • note

    The absence of reported adverse effects in animal studies does not guarantee safety in humans. The peptide modulates gene expression, which carries theoretical risks of unintended biological effects.

Drug interactions(6)

  • status

    Not formally studied in clinical trials

  • theoretical_concerns

    Anticoagulants/antiplatelets: Cardiogen contains Asp (aspartic acid) and Arg (arginine); arginine is a nitric oxide precursor that could theoretically potentiate vasodilatory effects of cardiovascular drugs

  • theoretical_concerns

    Antiarrhythmics: Cardiogen may influence calcium homeostasis and ion channel-related gene expression, potentially interacting with drugs like amiodarone or calcium channel blockers

  • theoretical_concerns

    Immunosuppressants: As a peptide that modulates gene expression, theoretical interactions with immunosuppressive therapies cannot be excluded

  • theoretical_concerns

    Chemotherapy agents: The tumor-modifying effects observed in animal models suggest caution with concurrent use of anti-cancer therapies

  • note

    No clinical drug interaction studies have been conducted. All interactions listed are theoretical based on known mechanisms of action. Patients on any cardiovascular medications should consult their physician.

Research & benefits

Evidence base

Evidence Level
Preclinical
Total Studies
8
Human Studies
0

Researched for(11)

Rated by confidence in the evidence

  • Stimulates expression of cytoskeletal proteins (actin, tubulin, vimentin) by 2-5x in fibroblast cultures

    Speculative

    Single mouse embryonic fibroblast study only, not replicated, not cardiac tissue.

    Khavinson V, Linkova N, Dyatlova A, Kantemirova R, Kozlov K. 'Senescence-Associated Secretory Phenotype of Cardiovascular System Cells and Inflammaging: Perspectives of Peptide Regulation.' Cells 2022 Dec 27;12(1):106 (PMID 36611900; PMC9818427) - verbatim: 'In cell culture of mouse embryonic fibroblasts, AEDR increased the synthesis of cytoskeletal proteins (actin, tubulin, and vimentin), by two to five times'

  • Enhances nuclear matrix protein expression (lamin A, lamin C) by 2-3x

    Speculative

    Same single embryonic fibroblast experiment, no independent confirmation or human data.

    Khavinson V et al., Cells 2022 Dec 27;12(1):106 (PMID 36611900; PMC9818427)

  • Stimulates cardiomyocyte proliferation in organotypic tissue cultures from both young and aged animals

    Low

    Two ex vivo rat tissue culture studies show increased proliferation in young and aged hearts.

    Adv Gerontol 2009 (PMID 20210190) - 'The effect of the amino acids and cardiogen on the development of myocard tissue culture from young and old rats'; Adv Gerontol 2006 (PMID 17152728) - tissue-specific effect of synthetic peptide bioregulators in organotypic culture, effective concentration 0.05 ng/ml

  • Suppresses apoptosis in myocardial cells via downregulation of p53 protein expression

    Low

    One rat organotypic culture study found reduced p53 expression, suggesting less apoptosis.

    Adv Gerontol 2009 (PMID 20210190) - cardiogen enhanced proliferation in myocardial tissue culture from young and old rats and reduced p53 protein expression, suggesting suppression of apoptosis

  • Proposed cardioprotective effects including preservation of myocardial glycogen stores

    Low

    Single rat infarct model showed reduced necrosis and preserved myocardial glycogen.

    Khavinson V et al., Cells 2022 Dec 27;12(1):106 (PMID 36611900) - verbatim: 'The drug administration in animals also resulted in the decrease in necrotic zones and preservation of glycogen content in the myocardial tissue.'

  • Potential protective effects on mitochondrial structures and enhancement of ATP synthesis

    Speculative

    Asserted in review only, no mitochondrial or ATP data published.

    Khavinson V et al., Cells 2022 Dec 27;12(1):106 (PMID 36611900) - verbatim: 'AEDR exerted a protective effect on mitochondria and stimulated reparative processes, which improved the cardiomyocyte metabolism.' No primary bioenergetic data located

  • May reduce fibroblast-mediated cardiac fibrosis by shifting fibroblast behavior toward less fibrotic phenotype

    Speculative

    Inferred from unrelated fibroblast data, no fibrosis outcome has been tested.

    Inference from Cells 2022 (PMID 36611900) embryonic fibroblast data; no fibrosis endpoint published for AEDR

  • Tissue-specific activity in rat cardiac explant cultures

    Speculative

    Functional tissue selectivity shown in culture, but no biodistribution study exists.

    Adv Gerontol 2006 (PMID 17152728) - tissue-specific organotypic activity of cardiogen, bronchogen, prostamax, pancragen; Cells 2022 (PMID 36611900) - AEDR detected in heart polypeptide complex by chromato-mass spectrometry; no biodistribution study located

  • Reported threefold mortality reduction in animal models of experimentally-induced coronary artery ligation

    Low

    Single rat infarct model reported threefold lower mortality, not independently replicated.

    Khavinson V et al., Cells 2022 Dec 27;12(1):106 (PMID 36611900) - verbatim: 'Administration of the AEDR peptide in experimental MI (ligation of the coronary artery in rats) led to a threefold decrease in mortality after the heart attack as compared to the control.'

  • Paradoxical pro-apoptotic effect on tumor cells in M-1 sarcoma model, suggesting selective action on healthy vs. diseased cells

    Speculative

    One rat sarcoma study, vascular mechanism proposed, not the selectivity claim itself.

    Levdik NV, Knyazkin IV. 'Tumor-modifying effect of cardiogen peptide on M-1 sarcoma in senescent rats.' Bull Exp Biol Med 2009;148(3):433-6 (PMID 20396706)

  • Regulation of inflammaging and senescence-associated secretory phenotype (SASP) markers in cardiovascular cells

    Speculative

    Discussed as a future research perspective, no direct SASP marker data.

    Khavinson V et al., 'Senescence-Associated Secretory Phenotype of Cardiovascular System Cells and Inflammaging: Perspectives of Peptide Regulation.' Cells 2022 Dec 27;12(1):106 (PMID 36611900) - review perspective, no AEDR SASP marker data

Benefits(11)

  • Stimulates expression of cytoskeletal proteins (actin, tubulin, vimentin) by 2-5x in fibroblast cultures

  • Enhances nuclear matrix protein expression (lamin A, lamin C) by 2-3x

  • Stimulates cardiomyocyte proliferation in organotypic tissue cultures from both young and aged animals

  • Suppresses apoptosis in myocardial cells via downregulation of p53 protein expression

  • Proposed cardioprotective effects including preservation of myocardial glycogen stores

  • Potential protective effects on mitochondrial structures and enhancement of ATP synthesis

  • May reduce fibroblast-mediated cardiac fibrosis by shifting fibroblast behavior toward less fibrotic phenotype

  • Tissue-specific activity in rat cardiac explant cultures; selective accumulation in the living heart has not been established by this experiment

  • Reported threefold mortality reduction in animal models of experimentally-induced coronary artery ligation

  • Paradoxical pro-apoptotic effect on tumor cells in M-1 sarcoma model, suggesting selective action on healthy vs. diseased cells

  • Regulation of inflammaging and senescence-associated secretory phenotype (SASP) markers in cardiovascular cells

Key studies(6)

  1. Khavinson VKh, Linkova NS, Polyakova VO, Kvetnoy IM, Benberin VV, Dyakonov MM, Titkov YuS

    Bulletin of Experimental Biology and Medicine

    2012

    AEDR tetrapeptide enhanced expression of cytoskeletal proteins (actin, tubulin, vimentin) by 2-5x and nuclear matrix proteins (lamin A, lamin C) by 2-3x in cultured mouse embryonic fibroblasts.

  2. Chalisova NI, Lesniak VV, Balykina NA, Urteva SA, Urteva TA, Sukhonos YuA, Zhekalov AN

    Advances in Gerontology

    2009

    Cardiogen at 10^-12 M stimulated proliferation in myocardial tissue cultures from both young (3-month) and aged (24-month) rats. Immunohistochemistry showed cardiogen lowered p53 protein expression, suggesting suppression of apoptosis.

  3. Levdik NV, Knyazkin IV

    Bulletin of Experimental Biology and Medicine

    2009

    Cardiogen increased apoptosis in M-1 sarcoma tumor cells in senescent rats through vascular mechanism alterations (hemorrhagic necrosis) rather than direct cytostatic effects.

  4. Zakutskii AN, Chalisova NI, Ryzhak GA, Aniskina AI, Filippov SV, Zeziulin PN

    Advances in Gerontology

    2006

    Cardiogen at 0.05 ng/ml showed stimulating effects in cardiac tissue cultures compared to controls in both young and aged rats, demonstrating tissue-specific bioregulatory activity.

  5. Khavinson VKh, Popovich IG, Linkova NS, Mironova ES, Ilina AR

    Molecules

    2021

    Systematic review confirming AEDR (Cardiogen) as a monofunctional peptide regulating cardiovascular system function. AEDR binds to histone proteins (H1, H2B, H3, H4) and modulates endonuclease-mediated DNA hydrolysis depending on methylation state.

  6. Khavinson V, Linkova N, Dyatlova A, Kantemirova R, Kozlov K

    Cells

    2022

    Review identifying AEDR tetrapeptide as a regulator of inflammaging and SASP-related molecule synthesis in cardiovascular system cells, with implications for age-associated cardiovascular pathology treatment.

Regulation & availability

Why researchers look at it

Rat myocardial cultures showed increased proliferation and reduced p53 expression, suggesting less apoptosis; a separate mouse embryonic fibroblast experiment found increased structural-protein expression — effects that could be relevant to age-related cardiac decline. A 2021 systematic review confirmed its binding to multiple histone proteins and ability to modulate DNA processing based on epigenetic state. No controlled human trials exist in peer-reviewed Western journals, with virtually all research from a single St. Petersburg institution.

Estimated cost
$30-80/mo oral capsules
FDA status
Not FDA approved. Cardiogen has not been evaluated, cleared, or approved by the U.S. Food and Drug Administration for any therapeutic indication, clinical use, or over-the-counter sale. No Investigational New Drug (IND) application is publicly known to be on file. In Russia, it is available as a non-prescription bioregulator supplement but has not undergone the rigorous Phase I-III clinical trial process required by Western regulatory agencies.
WADA status
Not individually named in the 2026 list. S0 prohibits pharmacological substances without governmental approval for human therapeutic use. Peptide identity alone does not establish S2 classification.
Prescribability
No. Cardiogen is not approved by the FDA or any major Western regulatory body for clinical use.
Availability
Also sold as a dietary supplement in Russia through the Khavinson Cytogen product line. Not available by prescription in Western countries. Not approved as a pharmaceutical in any major Western market.

International status

  • EU

    Not approved

  • US

    Not approved

  • Russia

    Used clinically (Khavinson bioregulator protocol)

  • Worldwide

    Limited to Russian clinical use

Regulatory timeline(9)

  1. 1960s-1990s
    Initial research on peptide bioregulators at the St. Petersburg (Leningrad) Institute of Bioregulation and Gerontology by Vladimir Khavinson and colleagues
  2. 2000s
    Cardiogen synthesized as a specific cardiac bioregulator tetrapeptide (AEDR); early in vitro and animal studies published
  3. 2006
    Tissue-specific bioregulatory effects demonstrated in organotypic cultures (Zakutskii et al., PMID 17152728)
  4. 2009
    Multiple studies published: myocardial tissue culture effects (PMID 20210190) and tumor-modifying effects (PMID 20396706)
  5. 2012
    Key study on cytoskeletal and nuclear matrix protein stimulation published (Khavinson et al., PMID 22977870)
  6. 2021
    AEDR included in systematic review of peptide gene regulation (Khavinson et al., Molecules, PMID 34834147)
  7. 2022
    AEDR reviewed in context of cardiovascular inflammaging and SASP (Khavinson et al., Cells, PMID 36611900)
  8. current_status
    IND submission status is unconfirmed. FDA generally does not disclose whether an IND exists unless it has previously been publicly disclosed or acknowledged.
  9. outlook
    Growing interest in bioregulator peptides in Western longevity medicine may accelerate clinical investigation, but formal regulatory pathway is likely years away. Independent replication of Russian preclinical findings by Western labs would be an important next step.

Sources & FAQs

Research sources(6)

Frequently asked questions(5)

What is Cardiogen?

Cardiogen is a synthetic tetrapeptide (four amino acids: Ala-Glu-Asp-Arg) developed by Russian scientist Vladimir Khavinson as a bioregulator peptide targeting cardiac tissue. It is designed to regulate gene expression in heart cells.

How does Cardiogen differ from other cardiac peptides like BNP or ANP?

Unlike natriuretic peptides (BNP, ANP) that act on cell surface receptors, Cardiogen is a short bioregulatory peptide that penetrates into cell nuclei and directly interacts with DNA and histone proteins to modulate gene transcription.

Has Cardiogen been tested in humans?

No controlled human clinical trials have been published in peer-reviewed Western journals. While some sources cite decades of clinical use in Russia, this has not been validated through randomized controlled trials meeting international standards.

Is Cardiogen safe?

In preclinical animal studies, Cardiogen was generally well-tolerated with no reported adverse effects. However, comprehensive human safety data are lacking. Without controlled clinical trials, the safety profile in humans remains uncharacterized.

Can Cardiogen repair a damaged heart?

Animal studies suggest Cardiogen may stimulate cardiomyocyte proliferation, reduce apoptosis, and potentially reduce necrotic zones after experimentally-induced myocardial infarction. However, these findings have not been confirmed in human trials, and claims of cardiac repair should be treated with caution.